학술논문
Clonal hematopoiesis associated with epigenetic aging and clinical outcomes
Document Type
article
Author
Nachun, Daniel; Lu, Ake T; Bick, Alexander G; Natarajan, Pradeep; Weinstock, Joshua; Szeto, Mindy D; Kathiresan, Sekar; Abecasis, Goncalo; Taylor, Kent D; Guo, Xiuqing; Tracy, Russ; Durda, Peter; Liu, Yongmei; Johnson, Craig; Rich, Stephen S; Van Den Berg, David; Laurie, Cecilia; Blackwell, Tom; Papanicolaou, George J; Correa, Adolfo; Raffield, Laura M; Johnson, Andrew D; Murabito, Joanne; Manson, JoAnn E; Desai, Pinkal; Kooperberg, Charles; Assimes, Themistocles L; Levy, Daniel; Rotter, Jerome I; Reiner, Alex P; Whitsel, Eric A; Wilson, James G; Horvath, Steve; Jaiswal, Siddhartha; Consortium, the NHLBI Trans‐Omics for Precision Medicine
Source
Aging Cell. 20(6)
Subject
Language
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is a common precursor state for blood cancers that most frequently occurs due to mutations in the DNA-methylation modifying enzymes DNMT3A or TET2. We used DNA-methylation array and whole-genome sequencing data from four cohorts together comprising 5522 persons to study the association between CHIP, epigenetic clocks, and health outcomes. CHIP was strongly associated with epigenetic age acceleration, defined as the residual after regressing epigenetic clock age on chronological age, in several clocks, ranging from 1.31 years (GrimAge, p 0 in both Hannum and GrimAge (referred to as AgeAccelHG+). This group was at high risk of all-cause mortality (hazard ratio 2.90, p